The modern pharmaceutical landscape is experiencing a significant transformation, moving beyond traditional low-molecular-weight compounds toward larger and more structurally sophisticated […]
Procurement Strategies for PLGA, PLA, PCL, and IND-Enabling Studies Supply Sourcing biodegradable polymers for IND-enabling studies requires the selection of
PLGA, PLA, and PCL for IND-Enabling Studies: What to Source and When Read More »
Introduction A formal nitrosamine risk assessment should begin during the preclinical stage of development, specifically during candidate selection and the
When Should You Start Nitrosamine Risk Assessment in Your Drug Development Program? Read More »
Introduction Developing reliable bioanalytical assays for emerging therapeutic modalities requires navigating an increasingly complex biophysical environment. When establishing analytical strategies
Introduction: Pharmacopoeial methods for nitrosamine testing were not purpose-built for the sensitivity levels modern regulators now demand. When the nitrosamine
Introduction The structural integrity and long-term stability of biopharmaceutical drug products depend heavily on the chemical inertness of their primary
Introduction Long-acting injectable (LAI) depot formulations based on biodegradable poly(lactide-co-glycolide) (PLGA) polymers represent one of the most effective technologies for
Drug–Polymer Interaction in Biosimilar Depot Formulations: LC-MS Insights Read More »
Introduction to Dexamethasone Development Challenges The development of sterile and stable dexamethasone injectable formulations demands careful management of numerous physical,
Common Failures in Dexamethasone Injectable Development Read More »
Introduction Within the increasingly competitive biopharmaceutical industry, performing a comprehensive Aggregation Analysis in Biosimilars is essential for establishing analytical similarity
Introduction to Data Integrity in Extractables and Leachables Testing Digital data integrity in extractables and leachables testing refers to the
